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Summary In vitro studies were initiated to study the antitumour effect of protein-doxorubicin (DXR)
conjugate on the growth of the multidrug resistant rat ascites hepatoma cell line, AH66DR. The 50%
inhibitory concentration (IC50) for DXR in AH66DR cell line was 16pmol l- (AH66 parental cell line,
AH66P, IC50 was 0.08 ymol I'). Treatment of AH66P and AH66DR cells with various concentations of
DXR or conjugates at equivalent concentrations of DXR was performed. The two types of conjugates used
were bovine serum albumin (BSA)-DXR conjugate and immunoglobulin G (IgG)-DXR conjugate. Both of
these conjugates showed potent dose-dependent inhibition of cell growth against AH66DR cells as compared
with the cells treated with DXR or other controls. The IC50 for BSA-DXR and IgG-DXR conjugates in
AH66DR cell line was 0.05 (equivalent DXR) JLmol 1-' and 0.07 (equivalent DXR) ymol l-', respectively.
These values were similar to that of the AH66P treated with DXR. Cellular uptake and accumulation of DXR
or BSA-DXR conjugate was also quantitated in both cell lines. The cellular concentration of DXR in
AH66DR cells was 2-fold lower than that of AH66P cells throughout the experiment. In contrast, by the
treatment of AH66DR cells with BSA-DXR conjugate, the intracellular drug concentration increased as a
function of time up to 24 h (639.1±41.8, equivalent DXR, ng lo- cells) and reached the same drug level as
AH66P cells treated with DXR (617.9± 17.3 ng -5 cells). Ammonium chloride treatment inhibited the effects of
the conjugates but did not inhibit the free drugs. Intracellular DXR was effluxed rapidly from AH66DR cells,
but BSA-DXR conjugate remained in the cells at relatively high concentration for a long time. These results
indicate that by chemically modifying DXR, such as by conjugation of the drug with proteins, it may be
possible to overcome multidrug resistance.
One of the major obstacles to successful chemotherapy of
cancer is multidrug resistance. Increased drug efflux out of
tumour cells has generally been implied as the mechanism
underlying drug resistance. Drug resitance has been assoc-
iated with overproduction of the drug-efflux pump, called gp
170 or P-glycoprotein (Pgp). In turn, there has been overex-
pression of the associated gene (Chen et al., 1986; Roninson,
1991). Various attempts to overcome multidrug resistance
have been studied (Beck, 1991; Chen et al., 1991). Most
experimental and clinical efforts to circumvent multidrug
resistance have used drugs such as verapamil, quinidine and
cyclosporine in an attempt to block the efflux function ofPgp
(Tsuruo et al., 1982; Twentyman et al., 1987; Hu et al.,
1990). Other investigators have attempted to use the mono-
clonal antibody against Pgp to modulate multidrug resistance
phenotype (Tsuruo et al., 1989; FitzGerald et al., 1987; Beck,
1991; Pearson et al., 1991). Some attempts have been made
to develop new drugs or to chemically modify existing drugs
in such a way as to decrease the energy-dependent drug efflux
pump and thereby increase tumour cell killing (Watanabe et
al., 1988; Sheldon et al., 1989; Coley et al., 1990; Ripamonti
et al., 1992).
In the present report we investigated the therapeutic
efficacy of the conjugates ofproteins and doxorubicin (DXR)
on growth of DXR resistant cell line in vitro.
Materials and methods
Cell line
The azo dye-induced rat ascites hepatoma cell line, AH66
parental cell line, AH66P, and the daunorubicin-resistant
mutant subline (AH66DR) were maintained in the RPMI
1640 media as described previously (Ohkawa et al., 1989a).
Both types of cells are minimally adherent to culture plates
and can be detached by pipetting. The AH66DR represented
a classic multidrug resistance line with cross-resistance to
DXR.
Preparation ofthe conjugates ofproteins and DXR
Binding of DXR to proteins were carried out using the
method described by Hurwitz et al. (1975). Briefly, 3 mg of
bovine serum albumin (BSA) or goat immunoglobulin G
(IgG) and 0.5 mg DXR (labelled with/without '4C) in 1 ml of
phosphate buffered saline was cross linked using glutar-
aldehyde solution. Free and bound drugs were separated by
gel filtration on Sephadex G-100 (Pharmacia, Uppsala,
Sweden). The degree of substitution was estimated by the
drug absorbance at 495 nm or by radioactivity. Protein con-
centration was measured by Bio-Rad protein assay kit (Bio-
Rad, Richmond, CA, USA). The conjugate ofglutaraldehyde
to BSA without DXR was also prepared.
Drug sensitivity assay
To assess drug resistance both types of AH66 viable cells
(2 x 104) were cultured in 24 wells culture plates (Corning,
NY, USA) with 1 ml of growth media containing graded
concentration of DXR continuously for 96 h. Cell viability
was determined by the trypan blue exclusion method at the
time of cell plating and at the end of the experiment. To
determine the effects of the conjugate and other controls,
viable cells (2 x 104) were also cultured with 1 ml of growth
media containing various concentrations of DXR or con-
jugates at equivalent concentrations of DXR. Studies were
also performed using the BSA-glutaraldehyde conjugate at an
equivalent BSA concentration as control. To investigate the
mechanism which was responsible for the cytotoxicity of the
conjugate drug, ammonium chloride (1Ommol 1' final con-
centration) known as lysosomotrophic amine, was added to
wells containing AH66DR cells 30 min before addition of
either DXR or the BSA-DXR conjugate. After incubation
with drugs for continuous 96 h, the viable cells were counted
by the dye exclusion method and results are expressed as the
increase in cell numbers in drug exposed cells as a percentage
of the increase in control cells.
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Uptake ofDXR or BSA-DXR conjugate
Viable AH66DR or AH66P cells (1 x 10') were incubated
with lltmol 1- of ['4C]-DXR (sp.act. 27,500 dpmpg-) or
BSA-[14C]-DXR conjugate (sp.act. 44,700 dpm Lg-l) contain-
ing growth media (2 ml) in culture tubes (Coming No. 25200)
with/without ammonium chloride (10mmol1` final concen-
tration) added 30 min before treatment. The incubation was
terminated by thorough washing with ice-cold 0.15 mol 1'
saline by centrifugation. After counting the viable cell
numbers, the cells were lysed by NCS (Amersham Japan,
Tokyo, Japan) and the amount of intracellular drug (Radio-
activity) was measured at various periods of time using a
liquid scintillation counter (LS6000IC, Beckman, Fullerton,
CA, USA).
Efflux ofDXR or BSA-DXR conjugate
For loading studies of DXR in AH66DR or AH66P cells,
both cells were cultured with 1 gmol 1I of ['4Cq-DXR in
Hanks' balanced salt solution for 1 h. NaN3 (5 mmol [` final
concentration) was added to the culture before addition of
DXR and not removed during drug treatment. For loading
studies of the BSA-DXR conjugate in the cells, AH66P and
AH66DR cells were cultured with 1 ytmol I` of BSA-[14C]-
DXR conjugate in growth media for 24 h. This amount of
time was necessary because of slow accumulation of the
conjugate. The drug-loaded cells were detached by pipetting
and were recovered by centrifugation, resuspended in 1 ml of
growth media (1 x 105 cells) and incubated for various
periods of time. After washing the cells with ice-cold saline,
radioactivity of the cells was counted by the method de-
scribed above. Results were expressed as a percentage of the
radioactivity in the cells at 0 time as compared to the radio-
activity in the cells obtained from various time intervals of
reincubation.
SDS-PAGE and Western blotting analysis
Cell extracts diluted in SDS-PAGE sample buffer were frac-
tionated using SDS-PAGE (7.5% separating gel) followed by
electrotransfer on the nitrocellulose paper as previously
reported (Ohkawa et al., 1989b). Resulting nitrocellulose
paper was incubated with mouse anti-Pgp monoclonal anti-
body (C219, Centocor, Malvern, PA, USA) followed by
horseradish peroxidase conjugated anti-mouse Ig (Bio-Rad).
Bands were visualized by ECL (Amersham).
Drugs and chemicals
DXR was kindly provided from Farmitalia-Carlo Erba
(Tokyo, Japan). BSA and goat IgG were purchased from
Sigma (St Louis, MO, USA). ['4C]-DXR (sp.act. 55 mCi
mmol- 1) was purchased from Amersham. All other chemicals
were of analytical grade.
Statistical analysis
Fisher's exact test was used.
Results
DXR sensitivity ofAH66DR cells
In the culture with continuous exposure to DXR for 96 h,
the 50% inhibitory concentration (IC50) for DXR in
AH66DR cells was 16gmol -', whereas the IC50 of AH66
parental cell was 0.08pmol I' (Figure 1). By SDS-PAGE
followed by Western blotting analysis, Pgp was detectable
only in the extract from AH66DR cells (Figure 2).
DXR conjugates toproteins
The extent of substitution varied in different preparations
and the conjugates with 3.28 moles DXR per mol BSA and
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Figure 1 Dose response curves of the AH66P (x) and the
mutant, AH66DR (A) cell line towards DXR by exposure for
continuous 96 h. Point, mean of duplicate experiments.
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Figure 2 SDS-PAGE, Westemn blotting analysis of Pgp in the
AH66DR (Lane 1) and AH66P (lane 2) cell extracts. MW:
molecular weight markers in kDa.
5.78 moles DXR per mol IgG obtained were used in the
present study.
The cytotoxic effect ofprotein-DXR conjugates on AH66DR
cells
The antitumour cytotoxic activity of BSA-DXR conjugates
to AH66DR cells was shown in the text Figure 3. We
observed that the BSA-DXR conjugate showed potent
growth inhibitory effect against AH66DR cells as compared
with that of DXR or BSA-glutaraldehyde. This effect was276 K. OHKAWA et al.
8 a dose-dependent. Phase-contrast microscopic examination
:,1.Cl><l5 t showed that dead cells were gradually increased and detect-
100
It 's 4>t able easily after 48 h of incubation with the conjugate. The
IC50 for BSA-DXR conjugate in AH66DR cell line was
0.05 tmol 1' at an equivalent DXR concentration. The
growth inhibitory effect of the conjugate was almost equiva-
0\ lent to that of the IC50 (0.08 lmol I') for DXR in the
\\ AH66P cell line. The BSA-DXR conjugate also showed
0 \\ excellent cytotoxic activity against AH66P cells (Figure 3,
o \\ IC50 = 0.0041lmol1). Pretreatment with ammonium chloride
did not increase or decrease the effects of free drug but
A \ \ moderately blocked the growth inhibitory effects of the con-
50 jugate (Figure 3).
IgG-DXR conjugate showed almost the same cytotoxic
:' \\ effect against AH66DR cells as did the BSA-DXR conjugate
(Figure 3).
Cellular uptake and accumulation ofthe drugs
8x_<, Drug uptake as a function of time in AH66P and AH66DR
*S< ° cells was evaluated at the 1 fimoll-I of [14C]-DXR or BSA-
0 o [14C]-DXR conjugate, at an equivalent DXR concentration of
0.01 0.1 1.0 1 ,tmol 1-1. Within 1 h of treatment with DXR, the cellular
drug concentration was approximately 2-fold higher (P<
0.05) in sensitive cells as compared to resistant cells and these
differences were maintained over 36 h. In contrast, when the
resistant AH66DR cells were treated with BSA-DXR con-
100 b jugate at doses which were equivalent to DXR, relatively
lower accumulation of drug was observed after 1 h of treat-
ment. The uptake of the BSA-DXR conjugate in AH66DR
2 \, cells increased gradually, but significantly (P<0.05), over a
24 h time period and approximately the same level of DXR
o (equivalent concentration) was observed as with the DXR in
o \ AH66P cells. Moderate to slight inhibition of the uptake of
| \ the conjugate (67.2-92.3% over a series of experiments) was
observed when AH66DR cells were co-cultured with ammon-
s50 | ium chloride-containing medium (Figure 4). In contrast,
mI\ 1 '4 ,there was no inhibition ofDXR-uptake between AH66DR or
:> \ \ \ AH66P cells which were co-cultured with ammonium chlor-
ide (data not shown).
Efflux of the drugs
Efflux of the conjugate from AH66DR (initial radioactivity,
\0 S 38,000dpm/105 cells) cells was found to be very slow with
0 . - _ greater than 90% of the initial concentration of drug remain-
0.001 0.01 0.1 1.0 ing in the cells. In contrast, very rapid transport of DXR out
of the AH66DR cells (initial radioactivity, 24,000 dpm/105
cells), approximately 70-75% was observed. The velocity of
the outward transport of DXR as well as BSA-DXR from
I C AH66P cells (initial radioactivity, 23,000 dpm/105 cells for
-_-._ C DXR and 31,000 dpm/105 cells for conjugate) was slow but
1'_,6 l_L.... 24 the efflux of the conjugate was slightly smaller than that of
100 * t t free DXR (Figure 5).
Discussion
o \\ Daunorubicin-resistant mutant cell line, AH66DR, has been
previously reported (Ohkawa et al., 1989a) to show cross-
0je [ \ { resistance to DXR with the associated overproduction of
o) 50\ m0 C ~~~~~~~~~~~~~~~Figure 3 The cytotoxic effect of free DXR at various concentra-
tions and conjugates at the equivalent concentration of DXR on
AH66DR (a, c) or AH66P (b) cells was examined in terms of
% \ ' percent surviving cell number as compared with that of control.
%
r \ + 1 Cultures were performed with (c) or without (a, b) addition of
% I1 mmol 1' ammonium chloride. For detail, see 'Materials and
methods'. Point, mean of triplicate determinations of three inde-
0% T.' pendent examinations; bar, s.d. (indicated unless smaller than the
0\ * point as plotted). a, AH66DR vs; BSA-glutaraldehyde - *
0 DXR A-, IgG-DXR 0 , BSA-DXR -0-. b, AH66P
0.01 0.1 10 ovs; DXR -*-, BSA-DXR 0-, IgG-DXR -A-. c,
AH66DR vs; DXR -A-, DXR with NH4CI
--A--, BSA-DXR
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Figure 4 Uptake of DXR or conjugate (equivalent concentration of DXR) in AH66P or AH66DR cells at different periods of
time. Each bar, mean ± s.d. of triplicate determinations of two independent examinations. -M Both cells treated with DXR,
Both cells treated with BSA-DXR conjugate, Eli Both cells treated with BSA-DXR conjugate plus ammonium chloride.
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Figure 5 Efflux ofDXR (open symbols) or BSA-DXR conjugate
(equivalent concentration of DXR, closed symbols) in AH66P
(square) or AH66DR (circle) cells at different periods of time.
Point, mean of duplicate determinations of two independent
examinations; bar, s.d.
Pgp. In the present study, we have demonstrated that the
chemical modification of DXR conjugated with BSA or IgG,
effectively increased its cytotoxic activity against DXR resis-
tant AH66DR cells. Additional studies showed that protein-
DXR conjugate-treated cells had higher intracellular DXR
concentration over a long period of time and that there was
also a slow decrease of intracellular drug concentrations in
the drug resistant AH66DR cells. It is somewhat difficult to
compare the velocity of the BSA-DXR conjugate efflux with
that of DXR efflux. This is because long term incubation of
the AH66DR cells with conjugate is required to load enough
drug into the cells to cause cell killing. These experiments
illustrate an important pharmacokinetics principle for drug
conjugates which is that there is a longer time needed for
higher accumulation and slow efflux of the conjugate occurs
in multidrug resistant cells. This conjugate was also cytotoxic
to AH66P cells. Expression of Pgp messenger RNA and
production of Pgp has been noted during hepatocarcino-
genesis and regeneration of rat liver. Pgp messenger RNA
has also been seen with hepatocellular carcinoma and sur-
rounding normal liver cells in humans (Thorgeirsson et al.,
1987; Ueda et al., 1987; Huang et al., 1992; Miyamoto et al.,
1992). Our results indicate that drug conjugates may be
useful for cancer chemotherapy of acquired multidrug resis-
tant cancer cells. They may also be useful to treat intrinsic
multidrug resistant cancer cells that are derived from cells
which express the Pgp on their cell membranes (Theibaut et
al., 1987).
The addition of ammonium chloride to the medium
moderately reduced the cytotoxic effect of the conjugate as
well as the intracellular accumulation of the conjugate. This
may be secondary to an inhibition of drug-uptake. It further
suggests that the growth inhibitory effects of the conjugate
involve the endocytosis of the conjugate and this may be
critically dependent on the low pH of the post-endocytotic
compartment. Our results clearly indicate that the pharma-
cokinetics of the chemically modified DXR are different in
intracellular behaviour from that of free DXR, which is
actively excreted from the cytoplasm by an energy-dependent
pump mechanism (Chen et al., 1986; Roninson et al., 1991;
Beck, 1991). It has been reported that the conjugates were
taken-up by endocytosis of the plasma membrane into the
cytoplasm and metabolised in the lysosomes (Trouet et al.,
1972; DeDuve et al., 1974; Shen & Ryser, 1979; Leserman et
al., 1981; Heath et al., 1983; Stahl, 1983; Waldmann, 1991).
We assume that the in vitro effectiveness of the protein-DXR
conjugate shown in AH66DR cells is via a similar mechan-
ism.
The improved drug sensitivity of multidrug resistant cells
to DXR conjugated with specific antibody against the cells or
to DXR-loaded nanosphares has been recently reported
(Sheldon et al., 1989; Cuvier et al., 1992). This report is
unique as it shows that conjugation of the drug, DXR, with
proteins produced a conjugate which could effectively inhibit
the growth of multidrug resistant cells which were demon-
strated to overproduce of Pgp in vitro. The method used to
conjugate the drug with protein was quite simple and we did
not observe any remarkable difference in the cytotoxic activ-
I
-o 600
0
-
0
400
Cu
"I
L.
2-00
0 l278 K. OHKAWA et al.
ity of the resultant conjugates between IgG and BSA as a
partner protein. For human use it would be possible to
substitute human serum albumin for either BSA or goat IgG.
To potentiate the cell killing activity of the conjugate it
would be desirable to increase the molar ratio of the drug
against the molar amount of protein. This could possibly be
accomplished by using improved methods for conjugation of
20-50 molecules of the drugs with one molecule of protein.
Examples of this include the immunoconjugates of IgG anti-
body against alpha-fetoprotein with anticancer drugs (Tsu-
kada et al., 1982; Kato et al., 1983; Tsukada et al., 1984;
Ohkawa et al., 1986). Further investigations in vitro are
planned to elucidate the exact mechanism(s) via which con-
jugates are able to overcome the multidrug resistance.
The authors wish to thank Dr H.T. Wepsic for his helpful advice
and criticism.
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